|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Tata Memorial Hospital Ministry of Science and Technology, India |
| Information provided by: | Tata Memorial Hospital |
| ClinicalTrials.gov Identifier: | NCT00123669 |
Purpose
The purpose of this study is to test the effect of primary progesterone on overall and disease free survival in women with operable breast cancer. The study addresses two issues related to breast cancer surgery:
| Condition | Intervention | Phase |
|
Breast Neoplasms |
Drug: Depot preparation of Hydroxyprogesterone hexanoate 500mg |
Phase III |
| Genetics Home Reference related topics: | breast cancer |
| MedlinePlus related topics: | Breast Cancer Cancer |
| ChemIDplus related topics: | Hydroxyprogesterone caproate Progesterone |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | The Primary Progesterone Therapy for Operable Breast Cancer : A Randomized Controlled Trial |
| Estimated Enrollment: | 1000 |
| Study Start Date: | October 1997 |
This protocol addresses the issue of pre-operative hormone manipulation in women with operable breast cancer. The study has been designed after careful review of literature to assess the effect of unopposed oestrogen at the time of surgery and collect evidence that events at the time of surgery may have impact on the long-term survival of breast cancer patients. The meta-analysis of 37 studies on timing of surgery during the menstrual cycle showed a 15% + 3 improvement in survival for women who had undergone surgery during the luteal phase of their menstrual cycle. Three of the 37 studies where progesterone levels were estimated at the time of surgery showed 52% + 26 improvement in survival when circulating progesterone were > 1.5 ng/ml. The study aims to produce luteal milieu by injecting Hydroxy- progesterone 500 mg IM at the time of surgery. The timing of administration of progesterone in the neo-adjuvant setting is decided after collating data from large data-bases and randomised trials of screening suggesting that events at the time of surgery may alter the behavior of micro-metastases.
Eligibility
| Ages Eligible for Study: | 18 Years to 75 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| India, Maharashtra | |||||
| Tata Memorial Hospital | |||||
| Mumbai, Maharashtra, India, 400012 | |||||
| Tata Memorial Hospital |
| Ministry of Science and Technology, India |
| Principal Investigator: | Rajendra A Badwe, M.S. | Professor & Head, Department of Surgical Oncology, Chief Breast Unit |
More Information
| Study ID Numbers: | No. SP/SO/B29/2000 |
| First Received: | July 21, 2005 |
| Last Updated: | August 1, 2005 |
| ClinicalTrials.gov Identifier: | NCT00123669 |
| Health Authority: | India: Science and Engineering Research Council |
|
|
|
|
|